Translation of "Patientenverbände" in English

Family members and patient associations have a crucial role to play in this context.

Patient associations were invited to participate in two ways.

This report brought together leading psychiatrists and advocacy groups to provide concrete recommendations for policy change.

It included medical and scientific research institutions, industry representatives and non-governmental patient coalitions from all EU.

The EESC proposes to organise a platform for patients' organisations to share experience and spread information.

Pradier collectively by politicians, particularly through associations for the sick.

The conference targets health ministers, politicians, government officials, patients organizations and health economists.

Member organisations are professional and patient associations, hospital associations, not-for-profit help for the elderly and manufacturers of Anthroposophic Medicines.

One such survey was conducted by the Coalition of the Organizations of Patients with Chronic Diseases in Romania.

General members include only patients’ associations with an interest in thalassaemia.

The following list details our support to patient organisations in previous years.

There are some patient associations which support the directive and there are others which oppose it.

While I am sympathetic to patient groups, many of the patient groups have come to me and said they were misrepresented.

Whether we speak about prevention, diagnosis, treatment, research or information, of course we speak about partnership, but we will manage to combat effectively the burden of cancer in Europe only if we make sure that all stakeholders - and particularly patients' groups - are involved in the long run, if we ensure an efficient exchange of good practices between Member States and if we guarantee that the functioning of such a partnership will be closely monitored and supported.

Commissioner, I look forward to seeing you tomorrow at Patients' Rights Day, because this is extremely important for all patients' groups, and your commitment matters to all of us.

In the light of this deteriorating situation, a group was set up at European level, bringing together consumer organisations, family organisations, patients' associations, insurance companies, and health insurance bodies. The 'Europe and Medicines' group has been working to provide information and clarification to European bodies and governments.

These decisions should be based on the active participation of stakeholders from the developing countries, scientific experts from the North and the South, representatives of patient groups, and the NGOs and the WHO.

Patients’ associations and non-governmental organisations are playing an increasingly important role, which justifies them receiving EU support.

The doctors' organisations, the patients' organisations throughout Europe are pleading with us not to specifically exclude paid donations.

We want to see better use made of the centres of reference across Europe and we are also pleased that NGOs and patients' organisations will have better access to funding thanks to this programme that will see emphasis placed on the wider environmental determinants of heath.

The Marketing Authorisation Holder (MAH) should ensure that, at launch, all Healthcare Professionals who are expected to prescribe/ use ReFacto AF, all laboratories that are expected to monitor patients receiving ReFacto AF and all EU Haemophiliac patients associations are provided with Educational packs.

The educational materials for Healthcare professionals, patients and haemophiliac patients associations should include the following key elements:

It also hopes that, in the interests of public health, a set of well-formulated and coordinated guidelines on best medical practice in various therapeutic fields and patient population strata, including the paediatric population, will be drafted in good time, with the active support of medical and patient associations.

Employer organisations, user groups and care workers and their representative organisations need to be involved in genuine processes of social dialogue to decide how care should be organised and delivered.

It also hopes that, in the interests of public health, a set of well-formulated and coordinated guidelines on best medical practice in various therapeutic fields and patient population strata, including the paediatric population, will be drafted in good time, with the active support of medical and patient associations.

These include patients’ organisations, consumer and citizen organisations, pharmaceutical industry organisations and companies, healthcare professionals, regulators, social insurance organisations, media organisations and individual citizens.

The participation of patients’ organisations in all aspects of the development of rare diseases policy is very important for identifying patients’ needs.

Additional expert advice was provided through the EU Health Policy Forum, health professionals and patients associations.

All interested parties, in particular patients associations, Member States competent authorities and industry associations, have been widely consulted on this proposal.

Article 4(1) of Regulation (EC) No 1901/2006 requires that the Commission appoint representatives of health professionals and patient associations to the European Medicines Agency (EMEA) Paediatric Committee.